Search for European Projects

14 European Projects Found

Searched on 125080 European Projects

 FINISHED 

Personalized diagnosis and treatment of hyperinsulinemic hypoglycaemia caused by beta-cell pathology (BETACURE)

Start date: Apr 1, 2014, End date: Mar 31, 2018,

Background:Hyperinsulinaemic hypoglycaemia (HH) is a potentially lethal disease caused by over functioning beta cells derived from the pancreatic islets of Langerhans. Lethal HH and brain damage is a problem especially in infants with congenital HH. Current therapeutic approaches are associated with severe side effects/morbidity (diabetes, exocrine pancreas insufficiency etc.) considered acceptabl ...
Read Project

 17

 FINISHED 

Genetics and epigenetics of Type 2 Diabetes physiology (GEPIDIAB)

Start date: Nov 1, 2012, End date: Oct 31, 2017,

"Failure to elucidate Type 2 Diabetes (T2D) physiology frustrates efforts to improve therapeutics. Although GWAS has identified 40 T2D genes, mostly expressed in pancreatic beta-cells, this explains no more than 10% of T2D inheritance. Up to 5% of T2D patients have dominantly inherited maturity-onset diabetes of the young (MODY), characterized by beta-cell dysfunction. Elucidating the genetics of ...
Read Project

 3

 FINISHED 

Universal Flu Vaccine (UNIVACFLU)

Start date: Nov 1, 2013, End date: Oct 31, 2017,

Currently licensed influenza vaccines promote an effective antibody response, but only against influenza virus strains that antigenically match the vaccine composition. Little protection is induced by these vaccines against antigenically drifted strains such as those emerging from an avian or swine reservoir. Hence there is a great need to develop broadly cross-reactive flu-vaccines.The aim is to ...
Read Project

 8

 FINISHED 

Chronotherapeutic lifestyle intervention for diabetes and obesity to reset the circadian rhythm and improve cardiometabolic risk in the European working population (EURHYTHDIA)

Start date: Oct 1, 2011, End date: Jun 30, 2017,

Modern lifestyle has dramatically changed the daily rhythms of life. Physical activity, diet and light exposure are no longer restricted to daytime hours, as technical and economical de-mands fuel the necessity to work outside usual working hours. Recent studies show that al-tered light exposure, shifted exercise patterns and untimely food intake following extended active periods into the night di ...
Read Project

 17

 FINISHED 

Development of biophotonic device based on flexible light emitting textile dedicated to the monitoring and treatment for dermatologic diseases and carcinoma (PHOS-ISTOS)

Start date: Dec 1, 2013, End date: Nov 30, 2016,

The therapeutic effect of the photodynamic therapy (PDT) depends on a combination of parameters that include drug dose, drug-light interval, oxygen in cells and light irradiance rate. It also varies according to the wavelength distribution of the light source. Finally, a homogeneous and reproducible illumination during the clinical PDT is determinant in preventing under- or overtreatment. So, the ...
Read Project

 12

 FINISHED 

Understanding food-gut-brain mechanisms across the lifespan in the regulation of hunger and satiety for health (Full4Health)

Start date: Feb 1, 2011, End date: Jan 31, 2016,

Full4Health is a multidisciplinary European collaboration of internationally renowned laboratories investigating the mechanisms of hunger, satiety and feeding behaviour, effects of dietary components and food structure on these processes, and their possible exploitation in addressing obesity, chronic disease and under-nutrition. The proposal integrates investigation of both human volunteers (dieta ...
Read Project

 16

 FINISHED 

Prediction of cognitive properties of new drug candidates for neurodegenerative diseases in the early clinical development (PHARMA-COG)

Start date: Jan 1, 2010, End date: Dec 31, 2015,

PHARMA-COG aims to develop a new integrated model to accelerate the development of drug cindidates for MS, PKD and AD. The innovation relies on a 'multidimensional matrix' approach, integrating all available and renewed inputs (biomarkers/animal, human models/physiological and pharmcological challenges, Phase 0/1/1b to reduce the attrition rate, to allow an early and pertinent GO/NOGO decision bef ...
Read Project

 38

 FINISHED 

Improving medical treatment adherence : taking into account patients' perception of uncertainty in the causal relationship between their adherence behaviour and their health condition (IMPROVINGADHERENCE)

Start date: Nov 1, 2012, End date: Oct 31, 2015,

Non-adherence, defined as the discrepancy between patients' behaviour and medical prescriptions, is a massive public health issue, the consequences of which are serious. Nearly half of the patients who have a chronic disease do not take their treatment as prescribed. In order to improve our understanding of this phenomenon and to remedy it, the proposed research will examine following hypothesis : ...
Read Project

 1

 FINISHED 

Beta Cell Therapy in Diabetes (BETACELLTHERAPY)

Start date: Jan 1, 2010, End date: Jun 30, 2015,

Type 1 diabetes is a serious chronic disease with major health risks and heavy burden on patients and society. It is caused by massive immune-mediated loss of insulin-producing beta cells in the pancreas that can so far not be locally corrected. A cellular allotransplant in the liver can install a new beta cell mass but the size is insufficient and the procedure faces limitations of donor shortage ...
Read Project

 18

 FINISHED 

COntinuous Multi-parametric and Multi-layered analysis Of DIabetes TYpe 1 & 2 (Commodity12)

Start date: Oct 1, 2011, End date: Jun 30, 2015,

In COMMODITY12 we will build a multi-layered multi-parametric infrastructure for continuous monitoring of diabetes type 1 and 2. The COMMODITY12 system will exploit multi-parametric data to provide healthcare workers and patients, with clinical indicators for the treatment of diabetes type 1 and 2. COMMODITY12 will focus on the interaction between diabetes and cardiovascular diseases. To address ...
Read Project

 11

 FINISHED 

CIVIL SOCIETY ORGANISATIONS IN DESIGNING RESEARCH GOVERNANCE (CONSIDER)

Start date: Feb 1, 2012, End date: Jan 31, 2015,

Broader stakeholder engagement in technical and scientific research is desirable for a variety of reasons. Civil Society Organisations (CSOs) can be optimal actors to realise the promise of participative research governance. Despite much activity to stimulate and implement CSO participation in research, there is no agreement on how to evaluate the success of participation.CONSIDER will undertake c ...
Read Project

 8

 FINISHED 

"Fungi in the setting of inflammation, allergy and autoimmune diseases:Translating basic science into clinical practices" (ALLFUN)

Start date: Dec 1, 2010, End date: May 31, 2014,

"The ALLFUN proposal aims at defining the cellular and molecular mechanisms by which ubiquitous airborne or commensal fungi contribute to immune homeostasis and its dysregulation leading to allergy and inflammatory diseases. Breakthroughs in understanding how mucosal homeostasis is established, maintained or disrupted in the presence of fungi should be sources of new therapeutic targets and drugs ...
Read Project

 14

 FINISHED 

Amélioration de l'efficaité et de la biodisponibilité des médicaments (Improving Drugs Efficacy and Availability) (IDEA)

Start date: May 31, 2009, End date: Jun 29, 2013,

Partners of the IDEA project will develop an original research activity programme with technical applications, to design new solid state pharmaceuticals. The purpose is to enhance the bioavailability, efficacy, chemical and physical stability, safety and predictability of both new and existing drugs.The IDEA project aims to position the 2 Seas area as an international leader in the solid state pha ...
Read Project

 6

 FINISHED 

Memory loss in Alzheimer disease: underlying mechanisms and therapeutic targets (MEMOSAD)

Start date: Jan 1, 2008, End date: Jun 30, 2011,

"MEMOSAD aims at defining the molecular mechanisms of Abeta- and Tau-induced synaptotoxicity and at developing disease-modifying therapeutics for the prevention of memory loss in Alzheimer disease (AD). Insoluble aggregates of the two proteins provide the pathological hallmarks of this incurable brain disorder. Early stage AD is characterized by a remarkably pure impairment of declarative memory a ...
Read Project

 10